Silo Pharma announced that the Japan Patent Office has issued a Notice of Allowance for its SPC‑15 intranasal therapeutic, a key asset in the company’s PTSD treatment pipeline. The allowance, titled “Compositions and Methods for the Prevention of Stress‑Induced Fear, Depression‑Like Behavior, and Anxiety‑Like Behavior,” confirms that the application meets all patentability requirements and will be granted shortly.
The approval expands Silo’s intellectual‑property portfolio in Japan, one of the world’s largest pharmaceutical markets, and bolsters the company’s global strategy to protect its lead asset. By securing protection in this jurisdiction, Silo enhances its ability to commercialize SPC‑15 and defend against potential competitors, reinforcing the dual‑strategy model that underpins the company’s growth prospects.
CEO Eric Weisblum said, “The approval of this patent is extremely important to Silo as it protects our lead asset while simultaneously bolstering our intellectual property portfolio.” He added that the allowance “reinforces the novelty of our approach to preventing stress‑induced behavioral disorders and expands our international patent estate in a highly significant pharmaceutical jurisdiction.”
Shares of Silo rose 3.99% on February 18, reflecting investor confidence in the company’s strengthened IP position and the broader potential for SPC‑15 in the Japanese market.
The patent allowance comes amid other strategic moves, including a non‑binding Letter of Intent with Allucent to conduct Phase 1 trials for SPC‑15 and a Nasdaq extension that gives the company until June 22, 2026 to regain compliance with the minimum bid price requirement. Together, these developments underscore Silo’s focus on advancing its PTSD portfolio while maintaining a diversified business model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.